WallStreetZenWallStreetZen

NYSEMKT: YCBD
Cbdmd Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for YCBD

Based on 1 analyst offering 12 month price targets for Cbdmd Inc

Min Forecast
$2.00+92.31%
Avg Forecast
$2.00+92.31%
Max Forecast
$2.00+92.31%

Should I buy or sell YCBD stock?

Based on 1 analyst offering ratings for Cbdmd Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although YCBD's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates YCBD as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their YCBD stock forecasts and price targets.

YCBD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-20

1 of 1

Forecast return on equity

Is YCBD forecast to generate an efficient return?

Company
-11.97%
Industry
208.42%
Market
356.86%
YCBD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is YCBD forecast to generate an efficient return on assets?

Company
-8.3%
Industry
113.5%
YCBD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

YCBD earnings per share forecast

What is YCBD's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.22
Avg 2 year Forecast
-$0.09

YCBD revenue forecast

What is YCBD's revenue in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$20.5M+6.94%
YCBD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

YCBD revenue growth forecast

How is YCBD forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
6.94%
Industry
3,776.02%
Market
1,548.38%
YCBD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
YCBD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

YCBD vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
YCBD$1.04$2.00+92.31%Strong Buy
GELS$0.97N/AN/A
BFRI$0.93N/AN/A
ZSTK$11.48N/AN/A
CABR$0.84N/AN/A
View Top Pharmaceutical Stocks

Cbdmd Stock Forecast FAQ

Is Cbdmd Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: YCBD) stock is to Strong Buy YCBD stock.

Out of 1 analyst, 1 (100%) are recommending YCBD as a Strong Buy, 0 (0%) are recommending YCBD as a Buy, 0 (0%) are recommending YCBD as a Hold, 0 (0%) are recommending YCBD as a Sell, and 0 (0%) are recommending YCBD as a Strong Sell.

If you're new to stock investing, here's how to buy Cbdmd stock.

What is YCBD's earnings growth forecast for 2026-2027?

(NYSEMKT: YCBD) Cbdmd's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 12,406.05%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,205.53%.

Cbdmd's earnings in 2026 is -$4,375,403.On average, 3 Wall Street analysts forecast YCBD's earnings for 2026 to be -$2,113,716, with the lowest YCBD earnings forecast at -$2,030,825, and the highest YCBD earnings forecast at -$2,175,884.

In 2027, YCBD is forecast to generate -$864,702 in earnings, with the lowest earnings forecast at -$830,792 and the highest earnings forecast at -$890,134.

What is YCBD's revenue growth forecast for 2026-2026?

(NYSEMKT: YCBD) Cbdmd's forecast annual revenue growth rate of 6.94% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3,776.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,548.38%.

Cbdmd's revenue in 2026 is $19,190,468.

In 2026, YCBD is forecast to generate $193,314,551 in revenue, with the lowest revenue forecast at $185,741,346 and the highest revenue forecast at $199,003,875.

What is YCBD's forecast return on assets (ROA) for 2026-2027?

(NYSEMKT: YCBD) forecast ROA is -8.3%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 113.5%.

What is YCBD's Price Target?

According to 1 Wall Street analyst that have issued a 1 year YCBD price target, the average YCBD price target is $2.00, with the highest YCBD stock price forecast at $2.00 and the lowest YCBD stock price forecast at $2.00.

The Wall Street analyst predicted that Cbdmd's share price could reach $2.00 by Aug 20, 2026. The average Cbdmd stock price prediction forecasts a potential upside of 92.31% from the current YCBD share price of $1.04.

What is YCBD's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: YCBD) Cbdmd's current Earnings Per Share (EPS) is -$1.09. On average, analysts forecast that YCBD's EPS will be -$0.22 for 2026, with the lowest EPS forecast at -$0.22, and the highest EPS forecast at -$0.23. In 2027, YCBD's EPS is forecast to hit -$0.09 (min: -$0.09, max: -$0.09).

What is YCBD's forecast return on equity (ROE) for 2026-2027?

(NYSEMKT: YCBD) forecast ROE is -11.97%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.